We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

News   Jun 02, 2009

 
Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
 
 
 

RELATED ARTICLES

Team Redesign Molecules To Fight Malaria

News

Redesigning molecules originally developed to treat the skin disease psoriasis could lead to an effective new drug against malaria, according to new study findings.

READ MORE

Evidence Reinforcing Approval of New Cancer Drugs Raises Questions

News

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, according to a new study.

READ MORE

Discussing the Pros and Cons of CRISPR

News

CRISPR technology has greatly facilitated gene editing. Associate Professor Thorsten Müller from Ruhr-Universität Bochum and Dr. Hassan Bukhari from Harvard Medical School discuss its pros and cons in a review article in the journal Trends in Cell Biology.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE